First-line treatment with ivonescimab led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with pembrolizumab (Keytruda) in patients ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback